PDS Biotech Posts Q3 Loss of $7.6M With $15.2M Cash and Zero Long-Term Debt
PDSB has more than doubled off its 52-week low of $0.195 on light trading volume (0.1× avg).
Summary
PDS Biotech reported a $7.6 million third-quarter net loss with $15.2 million of cash on September 30, 2026, and no long-term debt. R&D spending was cut to $2.1 million from $4.6 million a year earlier as PDS0301 became the lead program and PDS0101's Phase 3 was pushed toward partnering.
Key Events · Earnings and Guidance · PDSB
-
Q3 Loss Narrows to $7.6M
Net loss was $7.6 million, or $0.11 per basic and diluted share, versus $9.0 million, or $0.19 per share, in the third quarter of 2025.
-
Cash Falls to $15.2M
Cash and cash equivalents were $15.2 million at September 30, 2026, down from $26.7 million at December 31, 2025, against a $7.6 million quarterly net loss.
-
R&D Cut, Debt Eliminated
Research and development expense fell to $2.1 million from $4.6 million, and long-term debt dropped to zero from $11.7 million at year-end 2025; net interest expense rose to $1.7 million from $0.9 million.
-
PDS0301 Becomes Lead Program
Management designated PDS0301, the tumor-targeted IL-12 immunocytokine, as the lead development program, with PDS0101 Phase 3 to be pursued only through strategic partnerships or other external funding, including the one-year NantWorks exclusive license option.
Analysis · PDSB · Life Sciences
The balance sheet, not the income statement, is the quarter's headline. Cash stood at $15.2 million on September 30 against a $7.6 million quarterly net loss, leaving a short runway and continued reliance on the Nant-led PIPE and its ATM to fund PDS0301. Against that, the loss narrowed from $9.0 million a year ago because R&D spending was cut to $2.1 million from $4.6 million, and long-term debt fell to zero from $11.7 million at year-end after the Yorkville note was redeemed. Interest expense of $1.7 million is now a meaningful drag relative to a $5.9 million operating expense base. Management also formalized the strategic pivot: PDS0301 is now the lead program, while PDS0101's Phase 3 will only proceed through a partnership or other external funding, including the one-year NantWorks option to negotiate an exclusive PDS0101 license.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PDSB was trading at $0.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $102.9M. The 52-week trading range was $0.20 to $1.79. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.